# OnCo record ariceum-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/ariceum-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "ariceum-therapeutics" ;
  schema:name "Ariceum Therapeutics"@en ;
  schema:description "Ariceum Therapeutics is a Berlin company developing a treatment that carries the alpha-emitting isotope actinium-225 to small cell lung cancer and Merkel cell skin cancer. Its first human trial began in late 2025."@en ;
  schema:url <https://onco.cc/companies/ariceum-therapeutics/>, <https://www.biospace.com/press-releases/ariceum-therapeutics-appoints-david-schilansky-as-chief-executive-officer-and-announces-new-leadership-to-advance-next-phase-of-development> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.biospace.com/press-releases/ariceum-therapeutics-appoints-david-schilansky-as-chief-executive-officer-and-announces-new-leadership-to-advance-next-phase-of-development> ;
  schema:addressCountry "DE" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:sections <https://onco.cc/fronts/radiopharma/> ;
  onco:technologies <https://onco.cc/technologies/targeted-alpha-therapy/>, <https://onco.cc/technologies/radioligand-therapy/> .